Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Shionogi, ViiV Obtain Favorable Results in 3rd PIII Clinical Trial for Dolutegravir
November 15, 2012
- Healthcare Sales Soar 4.4% with Expansion of Abilify in Japan: Otsuka HD
November 15, 2012
- OrphanPacific to Initiate New Business Model “Contract MAH for Overseas Pharma”
November 15, 2012
- Japan’s 25 Major Drug Makers Log Contrasting Domestic Biz Results on Varying New Product Performances
November 14, 2012
- RaQualia to Slim Down Its Organization Considering Spinning Off Non-Core Development Programs
November 14, 2012
- Towa: 1st Half Sales Up 16%, But Less-than Expected Benefits from Generic Name Prescriptions
November 14, 2012
- Gap between Oncology MRs and Doctors Should Be Closed: Mr Mitsuhashi of Merck Serono
November 13, 2012
- CMIC HD Forms Business Partnership with Japanese Subsidiary of Leading CSO in Europe
November 13, 2012
- Ethical Drug Sales Down 4.9% in September: Crecon Report
November 13, 2012
- Tsumura Postpones Targeted Launch for Kampo Medicine Under Development in US
November 13, 2012
- GeneDesign to Comprehensively Support Development of Nucleic Acid Medicines through New CMC Research Center: Mr Sato
November 13, 2012
- Sawai Makes Downward Revision in Full-Year Sales Forecast Despite Increases in Sales, Profits in 1st Half
November 12, 2012
- Alliance with Choseido to Increase Nihon Chouzai’s Generic Lineup to 470: President Mitsuhara
November 12, 2012
- Tsumura Aims at Sales of 123 Billion Yen in FY 2015, to Expand Kampo Market: New Mid-Term Management Plan
November 12, 2012
- Sawai Sells off All Shares of Kyorin HD Following End of Talks for Business Integration
November 12, 2012
- Kaken Aims for Approval of Japan’s 1st Topical Onychomycosis Treatment Efinaconazole Next Year
November 12, 2012
- Time Will Tell Whether Once-monthly Products Ultimately Dominate or Merely Provide Another Option in the BP Market
November 12, 2012
- Sales Increase 3.4% as Generics Make Large Gains: Kyorin HD
November 9, 2012
- Novartis Files for Approval for LABA, LAMA Combination Treatment for COPD in Japan
November 9, 2012
- 1st-Half Settlements of Top 4 Wholesalers Suggest Recovery in Operating Profit Rates in Core Drug Business
November 9, 2012
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…